SECAUCUS, N.J., Aug. 12, 2024 /PRNewswire/ -- A new study by researchers from Quest Diagnostics (NYSE: DGX) and the University of Alabama suggests adherence to guideline-based laboratory testing and treatment of pregnant women for two of the most prevalent sexually transmitted infections (STIs) is suboptimal in the United States, with potentially dire effects on maternal and newborn health.
The study, titled Chlamydia and gonorrhea testing in pregnancy: Time to improve adherence and update recommendations, was published in the peer reviewed Journal of Lower Genital Tract Disease, the official journal of the American Society for Colposcopy and Cervical Pathology. It is based on deidentified results of lab tests performed by Quest in all 50 states and the District of Columbia for 4,077,212 pregnancies.
The findings suggest gaps in guideline-based care, intended to reduce the risk of infection and medical complications. Untreated chlamydia and gonorrhea can raise risks of infertility and pelvic inflammatory disease in women. The risk of transmission during birth is approximately 50%, raising the potential for newborns to develop infections of the eye (conjunctivitis), lungs (pneumonia) and other health problems.
"Our study adds to a troubling body of evidence highlighting inconsistent quality in maternal and child healthcare in the U.S.," said Damian P. Alagia, MD, co-author of the study and Medical Director of Women's Health at Quest Diagnostics. "Our analysis shows that improved adherence to existing recommendations, harmonization of guidelines across agencies, and even updated recommendations for STI testing will be critical to ensuring the mothers and babies in the United States receive medically appropriate testing and treatment."
Key findings:
The authors believe reinfections (or ineffectively treated initial infections) may result in an increased number of deliveries while women are positive with one or more STIs, which can impact both maternal and newborn health.
The authors conclude current guidelines are inconsistent and they provide several recommendations for improvements. For instance, the CDC recommends women be retested for cure at 4 weeks of pregnancy while the USPSTF recommends retesting before 3 weeks. Current guidelines also do not recommend screening women after the age of 25 years unless there are risk factors (such as multiple partners), based on a study from 1998 when women married at younger ages than today. Guidelines recommend that all women under the age of 25 be screened, regardless of perceived risk.
The study's strengths include its large size, national representation, and use of objective laboratory data. Its limitation is the lack of clinical follow-up information for the positive cases, as testing was limited to one national clinical laboratory. While the authors did not evaluate other STIs, such as syphilis, they caution these patterns of irregular adherence to guideline-based testing in maternal care may extend to other conditions.
According to the Centers for Disease Control and Prevention (CDC), cases of sexually transmitted disease are at an all-time high, with more than 2.5 million cases of syphilis, gonorrhea, and chlamydia reported in the United States in 2022.
About Quest Diagnostics
Quest Diagnostics works across the healthcare ecosystem to create a healthier world, one life at a time. We provide diagnostic insights from the results of our laboratory testing to empower people, physicians and organizations to take action to improve health outcomes. Derived from one of the world's largest databases of de-identifiable clinical lab results, Quest's diagnostic insights reveal new avenues to identify and treat disease, inspire healthy behaviors and improve healthcare management. Quest Diagnostics annually serves one in three adult Americans and half the physicians and hospitals in the United States, and our nearly 50,000 employees understand that, in the right hands and with the right context, our diagnostic insights can inspire actions that transform lives and create a healthier world. www.QuestDiagnostics.com.
For more Quest Diagnostics Health Trends® reports, visit www.Newsroom.QuestDiagnostics.com/Health-Trends.
Last Trade: | US$153.10 |
Daily Change: | 1.58 1.04 |
Daily Volume: | 1,050,209 |
Market Cap: | US$17.090B |
December 03, 2024 October 23, 2024 October 22, 2024 October 15, 2024 September 18, 2024 |
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MOREChimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB